Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 12, Issue 5, Pages 1092-1101Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2015.1129478
Keywords
anti-CTL-A4; ipilimumab; immunotherapy; melanoma treatment; toxicity
Categories
Ask authors/readers for more resources
In the last years the onset of new therapies changed the management of malignant melanoma. Anti CTLA-4 antibody ipilimumab was the first drug to achieve a significant improvement in survival of advanced stage melanoma. This new therapeutic agent is characterized by a number of side effects that are totally different from those of traditional chemotherapy, mainly caused by the immune system activation. The purpose of this paper is to underline the central role of ipilimumab in the treatment of metastatic melanoma and to characterize related adverse events in terms of incidence, duration and severity of presentation. The early recognition of these side effects is crucial in order to ensure an appropriate management of the toxicities, thus reducing the long term clinical sequelae and the inappropriate treatment discontinuation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available